The Mosaic vs FMC: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

The Mosaic Company (MOS)

Q3 202616 Jul – 17 Sep 2026

▼3

Mosaic's losses deepen as sulfur shortage cuts phosphate output

Sulfur shortage forces phosphate curtailments A sulfur shortage has fully idled Mosaic's Louisiana phosphate plant and slowed Florida operations, cutting third-quarter phosphate volumes to 1.1–1.4 million tons while sulfur costs jump to about $700–$710 per ton. Less product sold at higher input cost squeezes margins and pushes the stock down.
This is the core operating problem hitting Mosaic's biggest segment and its earnings power.
Q2 swung to a $273 million loss Mosaic posted a $273 million second-quarter net loss, reversing a $411 million profit a year earlier, with an operating loss of $36 million and adjusted EBITDA down to $407 million from $566 million. Phosphate and Fertilizantes both swung to operating losses; only Potash held steady.
The loss is the clearest evidence of how badly current fertilizer conditions are hurting Mosaic's bottom line.
New $450M phosphate plant would add competition CHS and OCP North America proposed a $450 million phosphate plant in Louisiana, the first new U.S. plant of its kind in over 40 years, producing over 1 million tons a year. That would add real competition for Mosaic, the largest U.S. phosphate producer, and pressure future prices.
A new domestic rival threatens Mosaic's dominant position and long-term pricing power.
Debt refinancing buys time but adds cost Mosaic tendered up to $1.4 billion of notes due 2027–2029 and issued $500 million of 5.650% notes due 2034, while also securing a $1 billion term loan, cutting 2026 capex to $1.2 billion and targeting a $300–$500 million working-capital release. This eases near-term liquidity but extends debt at higher coupons.
It shows how Mosaic is managing its balance sheet amid losses — supportive for survival, but not a fix for weak earnings.

August 202616 Jul – 17 Sep 2026

▼3

Mosaic's losses deepen as sulfur shortage cuts phosphate output

Sulfur shortage forces phosphate curtailments A sulfur shortage has fully idled Mosaic's Louisiana phosphate plant and slowed Florida operations, cutting third-quarter phosphate volumes to 1.1–1.4 million tons while sulfur costs jump to about $700–$710 per ton. Less product sold at higher input cost squeezes margins and pushes the stock down.
This is the core operating problem hitting Mosaic's biggest segment and its earnings power.
Q2 swung to a $273 million loss Mosaic posted a $273 million second-quarter net loss, reversing a $411 million profit a year earlier, with an operating loss of $36 million and adjusted EBITDA down to $407 million from $566 million. Phosphate and Fertilizantes both swung to operating losses; only Potash held steady.
The loss is the clearest evidence of how badly current fertilizer conditions are hurting Mosaic's bottom line.
New $450M phosphate plant would add competition CHS and OCP North America proposed a $450 million phosphate plant in Louisiana, the first new U.S. plant of its kind in over 40 years, producing over 1 million tons a year. That would add real competition for Mosaic, the largest U.S. phosphate producer, and pressure future prices.
A new domestic rival threatens Mosaic's dominant position and long-term pricing power.
Debt refinancing buys time but adds cost Mosaic tendered up to $1.4 billion of notes due 2027–2029 and issued $500 million of 5.650% notes due 2034, while also securing a $1 billion term loan, cutting 2026 capex to $1.2 billion and targeting a $300–$500 million working-capital release. This eases near-term liquidity but extends debt at higher coupons.
It shows how Mosaic is managing its balance sheet amid losses — supportive for survival, but not a fix for weak earnings.

Latest16 Jul – 17 Sep 2026

▼3

Mosaic's losses deepen as sulfur shortage cuts phosphate output

Sulfur shortage forces phosphate curtailments A sulfur shortage has fully idled Mosaic's Louisiana phosphate plant and slowed Florida operations, cutting third-quarter phosphate volumes to 1.1–1.4 million tons while sulfur costs jump to about $700–$710 per ton. Less product sold at higher input cost squeezes margins and pushes the stock down.
This is the core operating problem hitting Mosaic's biggest segment and its earnings power.
Q2 swung to a $273 million loss Mosaic posted a $273 million second-quarter net loss, reversing a $411 million profit a year earlier, with an operating loss of $36 million and adjusted EBITDA down to $407 million from $566 million. Phosphate and Fertilizantes both swung to operating losses; only Potash held steady.
The loss is the clearest evidence of how badly current fertilizer conditions are hurting Mosaic's bottom line.
New $450M phosphate plant would add competition CHS and OCP North America proposed a $450 million phosphate plant in Louisiana, the first new U.S. plant of its kind in over 40 years, producing over 1 million tons a year. That would add real competition for Mosaic, the largest U.S. phosphate producer, and pressure future prices.
A new domestic rival threatens Mosaic's dominant position and long-term pricing power.
Debt refinancing buys time but adds cost Mosaic tendered up to $1.4 billion of notes due 2027–2029 and issued $500 million of 5.650% notes due 2034, while also securing a $1 billion term loan, cutting 2026 capex to $1.2 billion and targeting a $300–$500 million working-capital release. This eases near-term liquidity but extends debt at higher coupons.
It shows how Mosaic is managing its balance sheet amid losses — supportive for survival, but not a fix for weak earnings.

FMC Corporation (FMC)

Q3 202630 Jul – 8 Oct 2026

▲3▼1

FMC cuts outlook on pricing, but debt cuts and new herbicide advance

Guidance cut on pricing pressure FMC lowered its 2026 revenue and profit outlook, blaming tough market conditions and falling prices for its crop chemicals. Full-year earnings per share are now expected to drop about 55% at the midpoint. Weaker profit expectations pull the stock down because investors pay for future earnings.
The guidance cut is the main new negative force on FMC's price this period.
Debt reduction progress lifts shares FMC is raising about $1 billion to pay down debt: a $400 million investment from Tessenderlo for a 20% stake, a $200 million upfront payment from Corteva, and a $252 million sale of its India business. Less debt means less risk, which helped the beaten-down stock jump 15.8%.
Debt reduction is the key positive force behind the period's sharp share rally.
New herbicide filed in Brazil FMC filed its rimisoxafen herbicide for approval in Brazil, a huge soybean and corn market, after a similar U.S. filing. It is the first herbicide with two ways of killing resistant weeds. Approval is uncertain and years away, but it supports future growth hopes.
The Brazil filing is a new pipeline event that supports FMC's long-term growth story.
Tessenderlo backs FMC as cornerstone investor Tessenderlo Group, fresh off a strong first half, confirmed its $400 million investment in FMC and its role as a cornerstone investor. A healthy, committed backer strengthens confidence in FMC's balance sheet and turnaround plan, though Tessenderlo also faces its own cost and currency pressures.
Tessenderlo's strong results reinforce confidence in its FMC investment, a positive capital signal.

September 202630 Jul – 8 Oct 2026

▲3▼1

FMC cuts outlook on pricing, but debt cuts and new herbicide advance

Guidance cut on pricing pressure FMC lowered its 2026 revenue and profit outlook, blaming tough market conditions and falling prices for its crop chemicals. Full-year earnings per share are now expected to drop about 55% at the midpoint. Weaker profit expectations pull the stock down because investors pay for future earnings.
The guidance cut is the main new negative force on FMC's price this period.
Debt reduction progress lifts shares FMC is raising about $1 billion to pay down debt: a $400 million investment from Tessenderlo for a 20% stake, a $200 million upfront payment from Corteva, and a $252 million sale of its India business. Less debt means less risk, which helped the beaten-down stock jump 15.8%.
Debt reduction is the key positive force behind the period's sharp share rally.
New herbicide filed in Brazil FMC filed its rimisoxafen herbicide for approval in Brazil, a huge soybean and corn market, after a similar U.S. filing. It is the first herbicide with two ways of killing resistant weeds. Approval is uncertain and years away, but it supports future growth hopes.
The Brazil filing is a new pipeline event that supports FMC's long-term growth story.
Tessenderlo backs FMC as cornerstone investor Tessenderlo Group, fresh off a strong first half, confirmed its $400 million investment in FMC and its role as a cornerstone investor. A healthy, committed backer strengthens confidence in FMC's balance sheet and turnaround plan, though Tessenderlo also faces its own cost and currency pressures.
Tessenderlo's strong results reinforce confidence in its FMC investment, a positive capital signal.

Latest30 Jul – 8 Oct 2026

▲3▼1

FMC cuts outlook on pricing, but debt cuts and new herbicide advance

Guidance cut on pricing pressure FMC lowered its 2026 revenue and profit outlook, blaming tough market conditions and falling prices for its crop chemicals. Full-year earnings per share are now expected to drop about 55% at the midpoint. Weaker profit expectations pull the stock down because investors pay for future earnings.
The guidance cut is the main new negative force on FMC's price this period.
Debt reduction progress lifts shares FMC is raising about $1 billion to pay down debt: a $400 million investment from Tessenderlo for a 20% stake, a $200 million upfront payment from Corteva, and a $252 million sale of its India business. Less debt means less risk, which helped the beaten-down stock jump 15.8%.
Debt reduction is the key positive force behind the period's sharp share rally.
New herbicide filed in Brazil FMC filed its rimisoxafen herbicide for approval in Brazil, a huge soybean and corn market, after a similar U.S. filing. It is the first herbicide with two ways of killing resistant weeds. Approval is uncertain and years away, but it supports future growth hopes.
The Brazil filing is a new pipeline event that supports FMC's long-term growth story.
Tessenderlo backs FMC as cornerstone investor Tessenderlo Group, fresh off a strong first half, confirmed its $400 million investment in FMC and its role as a cornerstone investor. A healthy, committed backer strengthens confidence in FMC's balance sheet and turnaround plan, though Tessenderlo also faces its own cost and currency pressures.
Tessenderlo's strong results reinforce confidence in its FMC investment, a positive capital signal.